MedicarePartD.guide

A non-government resource built from CMS public data

TNF blockers on every 2026 Illinois Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 12 stand-alone Part D plans in Illinois cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days

12 plans, cheapest premium first. Scroll sideways for all of them →

TNF blockers by 2026 Illinois Part D plan
DrugWellcare Classic$0.00/moS4802-087Wellcare Value Script$0.00/moS4802-151Humana Basic Rx Plan$0.00/moS5884-107Humana Value Rx Plan$0.00/moS5884-196AARP Medicare Rx Saver from UHC$40.20/moS5921-362HealthSpring Extra Rx$66.60/moS5617-367Blue Cross MedicareRx Basic$89.70/moS5715-012SilverScript Choice$94.90/moS5601-034AARP Medicare Rx Preferred from UHC$103.90/moS5921-398HealthSpring Assurance Rx$104.20/moS5617-224Humana Premier Rx Plan$119.40/moS5884-163Blue Cross MedicareRx Value$119.70/moS5715-001
HumiraadalimumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 52/365dNot coveredNot coveredNot coveredNot covered
adalimumab biosimilarsadalimumab-adaz, -fkjp, -aacf and othersTier 5PA25%QL 4/28dTier 5PA25%QL 4/28dTier 5PA25%QL 0.2/28dTier 5PA26%QL 0.2/28dTier 5PA25%Not coveredNot coveredNot coveredTier 5PA31%Not coveredTier 5PA33%QL 0.2/28dNot covered
Hadlimaadalimumab-bwwdNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 2.4/28dTier 5PA25%QL 2.4/28dTier 5PA25%QL 22.4/365dNot coveredTier 5PA25%QL 2.4/28dNot coveredTier 5PA25%QL 2.4/28d
Hyrimozadalimumab-adazNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Cyltezoadalimumab-adbmTier 5PA25%QL 4/28dTier 5PA25%QL 4/28dNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Simlandiadalimumab-ryvkNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 3/28dNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 3/28d
Yuflymaadalimumab-aatyTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Amjevitaadalimumab-attoNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
EnbreletanerceptTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA26%QL 8/28dTier 5PA25%QL 4/28dTier 5PA25%QL 8/28dTier 5PA25%QL 2/28dTier 5PA25%QL 8/28dTier 5PA31%QL 4/28dTier 5PA25%QL 8/28dTier 5PA33%QL 8/28dTier 5PA25%QL 2/28d
Cimziacertolizumab pegolNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
SimponigolimumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.